Ark Therapeutics to take more gene-based products into man in 2009

Following positive Phase 3 data for its gene therapy for brain cancer, Ark Therapeutics plans to take three more gene-based medicines into the clinic in 2009. All three use an adenoviral vector platform to deliver a gene treatment.